MolProbity Ramachandran analysis

MolProbity Ramachandran analysis
1F4H, model 1
General case
180
C 77 ASP
493ASP
THR
CA D
211
732
ALA
BC 77
ASP
690
SER
A 890
GLN
C 743 SER
Isoleucine and valine
180
C
81 ALA
B 690
SER
B 734 SER
A SER
734 SER
C 734
Psi
D 909 ARG
A 540 HIS
B 733 ALA
C 733 ALA
461GLU
GLU
D A647
AD 461
733SER
ALA
C 461 GLU
B D65914ASP
ARG
A 647 SER
D 667 GLU
B 891 VAL
Psi
109ILE
VAL
CD 208
B 383 ASN
BD 546
546LEU
LEU
A 580
541 GLU
ALA
A
A
601 ASP
PHE
CB 252
601
PHE
0
B 164 ASP
0
B601
SER
AD
PHE
11
LEU
C174
252
ASP
831 ASP
ALA
CB 996
B 930 VAL
D
72
SER
A233
1005
ALA
CBD
ASP
95
TYR
A
SER
C
815
425
HIS
ARG
D 174
174
SER
B
398
TRP
CB
425
12
GLN
ARG
C 376 ILE
A 10 VAL
D 10 VAL
A 599 ARG
C 746 ASP
C 916 ASP
DCC493
THR
742
493
THR
THR
-180
-180
0
Phi
Pre-proline
180
-180
180
-180
0
Phi
180
Phi
180
Phi
180
Glycine
180
D 488 GLY
D 687 GLN
Psi
Psi
0
0
C 46 ARG
-180
-180
-180
0
Phi
180
Trans proline
180
-180
0
Cis proline
180
C 731 PRO
D 273 PRO
B 688 PRO
C 788 PRO
PRO
C D47669
PRO
B 119 PRO
Psi
Psi
C 119 PRO
A 119 PRO
0
0
D 948 PRO
A 79 PRO
B 79 PRO
B 434 PRO
C 79 PRO
D 686 PRO
-180
-180
-180
89.6% (3652/4076) of all residues were in favored (98%) regions.
98.0% (3993/4076) of all residues were in allowed (>99.8%) regions.
C
C 208 ILE (-61.4, 89.0)
C 211 ASP (-47.8, 165.2)
C 461 GLU (23.3, 68.8)
C 493 THR (-51.7, -175.5)
C 601 PHE (-50.1, -5.0)
C 690 SER (-34.3, 154.3)
A 601 PHE (-42.0, -22.8)
A 647 SER (-54.5, 56.0)
A 733 ALA (-56.8, 73.2)
C 731 PRO (-35.4, 163.3)
C 733 ALA (16.3, 86.5)
C 734 SER (-15.7, 115.4)
A 734 SER (9.0, 120.8)
A 890 GLN (-38.1, 150.9)
C 742 THR (-57.3, -175.5)
C 743 SER (157.7, 175.6)
79 PRO (-22.9, -28.7)
95 TYR (-20.7, -57.8)
0
C 746 ASP (163.3, -171.9)
C 788 PRO (-33.1, 140.7)
C 916 ASP (171.2, -178.3)
C 996 ASP (-33.7, -34.9)
B 119 PRO (-32.4, 118.7)
B 164 ASP (105.5, 79.8)
D
D
B 174 SER (-33.7, -21.9)
B 383 ASN (87.1, 27.6)
D 14 ARG (23.9, 60.4)
D 72 SER (-26.2, -50.2)
B 398 TRP (-22.4, -62.5)
B 425 ARG (-19.7, -63.5)
D 109 VAL (-58.5, 94.2)
D 174 SER (-18.6, -61.2)
B 434 PRO (-72.2, -58.7)
B 546 LEU (92.4, 16.4)
D 273 PRO (-120.0, 159.9)
D 461 GLU (21.3, 80.5)
10 VAL (-49.6, -82.0)
11 LEU (-34.2, -24.6)
B 601 PHE (-48.6, 0.2)
B 659 ASP (13.5, 62.9)
D 488 GLY (-39.9, 153.4)
D 493 THR (-61.0, -173.9)
B 688 PRO (-110.2, 151.4)
B 690 SER (-27.2, 132.9)
B 733 ALA (-25.3, 91.6)
D 546 LEU (95.1, 15.8)
D 647 SER (-64.7, 78.5)
D 667 GLU (158.5, 86.8)
B 734 SER (-8.0, 126.5)
B 831 ALA (-31.5, -32.1)
D 669 PRO (-107.2, 132.0)
D 686 PRO (-52.7, -149.1)
B 891 VAL (-161.4, 102.0)
B 930 VAL (-21.7, -44.1)
D 687 GLN (159.7, 117.8)
D 732 ALA (-35.8, 162.1)
C
C
D 815 HIS (-17.0, -59.2)
D 909 ARG (-170.9, 59.6)
12 GLN (-21.6, -63.2)
46 ARG (-75.0, -159.7)
-180
C 233 ASP (-25.0, -54.1)
C 252 ASP (-27.3, -26.9)
C 376 ILE (-42.8, -70.7)
C 425 ARG (-10.3, -59.2)
A 540 HIS (-60.4, 95.3)
A 541 ALA (-63.6, 13.0)
A 580 GLU (-63.7, 10.5)
A 599 ARG (35.3, -135.5)
B
B
180
C 77 ASP (-54.0, 175.1)
C 79 PRO (-30.2, -83.0)
C 81 ALA (-28.1, 134.4)
C 119 PRO (-48.5, 91.7)
A 79 PRO (-98.5, -34.4)
A 119 PRO (-40.1, 83.6)
A 461 GLU (15.2, 77.5)
A 493 THR (-44.9, 169.0)
A 1005 ALA (-15.9, -53.5)
B 77 ASP (-40.0, 158.1)
Phi
47 PRO (-117.9, 130.7)
There were 83 outliers (phi, psi):
A 10 VAL (-51.9, -75.4)
A 174 SER (-24.2, -58.2)
A 252 ASP (-52.9, -0.8)
0
D 948 PRO (-99.3, -26.1)
http://kinemage.biochem.duke.edu
Lovell, Davis, et al. Proteins 50:437 (2003)